Application of Intraperitoneal Hyperthermic Chemotherapy after Surgery for Gastrointestinal Malignancies
Discuss the efficacy of intraperitoneal hyperthermic chemotherapy after surgery for gastrointestinal malignancies. Method: Select 60 patients with stage II to IV gastrointestinal malignancies after surgery, with 32 cases as the treatment group receiving intraperitoneal hyperthermic chemotherapy + intravenous chemotherapy, and 28 cases as the control group receiving conventional intravenous chemotherapy. Results: The intraperitoneal recurrence rate and metastasis rate in the treatment group were significantly lower than those in the control group (P
Release time:
2022-08-26
Source:
Discuss the efficacy of intraperitoneal hyperthermic chemotherapy after surgery for gastrointestinal malignancies. Method: Select patients with stage II to IV gastrointestinal malignancies after surgery.
60 cases, with 32 cases as the treatment group receiving intraperitoneal hyperthermic chemotherapy + intravenous chemotherapy, and 28 cases as the control group receiving conventional intravenous chemotherapy. Results: The intraperitoneal recurrence rate and
metastasis rate in the treatment group were significantly lower than those in the control group (P<0.01). The 3-year and 5-year survival rates in the treatment group were significantly higher than those in the control group (P<0.01). Conclusion: Intraperitoneal hyperthermic chemotherapy + intravenous chemotherapy after surgery for gastrointestinal malignancies not only effectively reduces intraperitoneal recurrence and metastasis but also improves the 3-year and 5-year survival rates.